Research progress on N6-methyladenosine RNA modification in osteosarcoma: functions, mechanisms, and potential...

Area of Science:

• Epigenetics and Molecular Oncology
• Cancer Biology
• RNA Modifications

Background:

• Osteosarcoma (OS) is a primary malignant bone tumor with a poor prognosis, particularly in pediatric and adolescent populations.
• Despite therapeutic advancements, OS remains highly invasive and challenging to treat effectively.
• N6-methyladenosine (m6A) modification, a prevalent RNA epigenetic mark, is increasingly recognized for its significant involvement in OS pathogenesis.

Purpose of the Study:

• To provide a comprehensive review of m6A regulators (methyltransferases, demethylases, binding proteins) in the context of osteosarcoma.
• To elucidate the dual role of m6A modifications in either promoting or inhibiting OS progression.
• To explore the mechanistic involvement of m6A-modified RNAs in key oncogenic signaling pathways.

Main Methods:

• Literature review and synthesis of existing research on m6A modification and osteosarcoma.
• Detailed analysis of m6A regulators' expression and function in OS.
• Examination of m6A-mediated regulation of mRNA and ncRNA in critical signaling pathways (Wnt/β-catenin, PI3K/AKT, STAT3).

Main Results:

• Abnormal expression of m6A regulators is frequently observed in osteosarcoma.
• m6A modifications can exert both oncogenic and tumor-suppressive effects in OS.
• m6A-modified mRNAs and ncRNAs are integral components of major OS signaling pathways.

Conclusions:

• m6A regulators represent promising biomarkers for osteosarcoma diagnosis and prognosis.
• Targeting m6A regulators offers a potential novel therapeutic strategy for osteosarcoma.
• Further research into m6A modification mechanisms can provide new insights for OS treatment.